Sales traction from Botanix Pharmaceuticals' (ASX:BOT) full commercial launch of Sofdra, its prescription treatment for excessive underarm sweating, could lead to a potential stock rating above its price target, according to a Monday note by Euroz Harlteys.
On Jan. 31, the company said that the full commercial launch of Sofdra is officially underway, with sales professionals set to hit the field within the next week.
Early patient feedback from social media and online sources shows that Sofdra is effective compared to its alternatives, with minimal side effects, with patients receiving full insurance coverage, Euroz said.
The feedback is positive for BOT and raises Euroz's confidence in the company's ongoing commercial rollout.
Euroz maintained Botanix Pharmaceuticals' buy rating and its AU$0.55 price target.
Shares of the company rose 7% at market close.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。